Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 2199
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Bcl2
Name: BCL2, apoptosis regulator
Acc ID: CHEBI:52717
Term: bortezomib
Definition: L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome.
Chemical ID: MESH:D000069286
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Bcl2decreases expressionISOBCL2 (Homo sapiens)6480464CTDBortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 proteinPMID:16022909 PMID:16446371 PMID:17156654 PMID:17327374 PMID:18928586 PMID:20383943
Bcl2increases cleavageISOBCL2 (Homo sapiens)6480464CTDBortezomib results in increased cleavage of BCL2 protein modified formPMID:16118318
Bcl2increases expressionISOBCL2 (Homo sapiens)6480464CTDBortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 proteinPMID:17895889 PMID:20051518
Bcl2multiple interactionsISOBCL2 (Homo sapiens)6480464CTD[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]PMID:15173093 PMID:15781649 PMID:16118318 PMID:17326159 PMID:17351739 PMID:18718063 PMID:20471514 PMID:21302442 PMID:24377552
Go Back to source page   Continue to Ontology report